Exciting Announcement from Stereotaxis
ST. LOUIS, Oct. 21, 2025 – Stereotaxis (NYSE: STXS), known for its pioneering efforts in surgical robotics for minimally invasive endovascular interventions, is preparing to unveil its financial outcomes for the third quarter of 2025. The announcement is set for November 11, 2025, just after the U.S. stock markets close. This date marks an important moment for the company and its stakeholders.
Conference Call Details
When and How to Join
The conference call will start at 4:30 p.m. ET, providing insights into the company's financial performance and strategic developments. Investors and analysts are encouraged to participate by dialing 800-715-9871 for those in the U.S. and Canada, or 646-307-1963 for international attendees. To ensure access to the call, have the participant pass code 4402192 ready.
Webcast Access
For those who prefer an online experience, Stereotaxis will also hold a webcast. Attendees can access the live stream and later replay by visiting Stereotaxis’ investor relations section. This feature ensures that everyone can stay updated with the latest financial information and corporate developments.
Voice of Experience: Call Replay
Should you be unable to join the conference call live, fear not! A replay will be available for one month post-call, enabling investors to review the discussions and financial insights shared. Accessing the replay is simple; instructions will be provided during the live session, ensuring you won’t miss a thing.
About Stereotaxis and Its Innovation
Stereotaxis (NYSE: STXS) is not just any company; it stands at the forefront of surgical robotics, dedicated to transforming the landscape of medicine through minimally invasive interventions. Their innovative solutions are designed to enhance patient care, elevate safety in procedures, and provide surgeons with advanced tools that promote efficiency and precision. This commitment to excellence has already benefited over 150,000 patients globally, reinforcing their role as industry leaders.
Mission-Driven Approach
The mission of Stereotaxis revolves around continuous discovery and development of robotic systems and instruments tailored for interventional laboratories. This forward-thinking approach shines a light on their ethos: to ensure enhanced access to therapy while revolutionizing operational intelligence in medical settings.
Join the Stereotaxis Community
For those seeking deeper engagement, Stereotaxis welcomes you to explore their advanced robotic technologies. Their website is brimming with information that underscores their dedication to enhancing patient outcomes and supporting healthcare providers worldwide. Simply visit their official site to learn more.
Meet the Leaders of Stereotaxis
At the helm of Stereotaxis are dedicated professionals committed to the company's vision and its shareholders. David L. Fischel serves as the Chairman and Chief Executive Officer, guiding the strategic direction of the organization. Alongside him is Kimberly Peery, the Chief Financial Officer, ensuring robust financial stewardship amidst the company’s growth trajectory.
Frequently Asked Questions
What are the upcoming financial results for Stereotaxis?
Stereotaxis is set to release its financial results for the third quarter of 2025 on November 11, 2025.
How can I participate in the conference call?
You can join by calling 800-715-9871 for U.S. and Canada, or 646-307-1963 internationally, using pass code 4402192.
Will there be a replay available?
Yes, a recording of the call will be available for one month after the event.
What is the primary focus of Stereotaxis?
Stereotaxis focuses on innovative surgical robotics aimed at minimally invasive endovascular interventions.
Who are the key executives at Stereotaxis?
David L. Fischel is the Chairman and CEO, and Kimberly Peery serves as the CFO.
